Moderna agreed to settle long-running patent litigation over lipid nanoparticle (LNP) delivery technology, resolving claims by Arbutus Biopharma and Roivant subsidiary Genevant. The company will pay $950 million up front and faces up to $2.25 billion in contingent payments while receiving a global non‑exclusive license for certain infectious-disease uses. The settlement clears a major legal overhang for Moderna’s vaccine portfolio — Spikevax and other mRNA programs — by licensing core LNP patents. Roivant and Arbutus framed the deal as recognition of their contributions to mRNA delivery; Moderna described the pact as legal certainty that lets it focus on product development and commercialization. Industry observers expect the resolution to reduce litigation risk for other mRNA developers and to affect downstream licensing negotiations for LNP platforms worldwide.